MESENCHYMAL STEM CELLS INDUCED TO DIFFERENTIATE IN THE OSTEOGENIC DIRECTION

The biomedical cell product is adult mesenchymal stem cells with confirmed differentiation in the osteogenic direction (hereinafter referred to as MSCO). Along with the main therapeutic properties of multipotent mesenchymal stem cells, MSC are able to initiate and maintain the process of local osteogenesis.
The optimal biomaterial for the isolation of native MSC in an adult for the purpose of their further cultivation and subsequent targeted osteoinduction is adipose tissue. Due to the ability of MSC to actively proliferate in vitro, it is always possible to obtain a cell dose sufficient for successful clinical use. To confirm the osteogenic differentiation of MSC, the most reliable technology is used – the method of real-time polymerase chain reaction (PCR).
The application of MSCO to biocompatible carrier materials, such as collagen, makes it possible to create simple tissue engineering constructs for effective reparative osteogenesis in vivo.
One of the areas of application of MSCO is traditionally considered to be dentistry, in particular, the treatment of periodontal diseases. Pathological changes in chronic periodontitis, leading to the destruction of the bone structures of the tooth socket, are a natural field of activity for regenerative technologies.
After local transplantation of MSCO on a collagen membrane into the periodontal pocket, the process of regeneration and formation of bone tissue begins. The activity of MSCO ensures the launch of reparative osteohistogenesis. The angiogenic activity of MSCO with the formation of a new microvasculature in healthy tissues surrounding the tooth stimulates the recruitment and proliferation of resident mesenchymal cells of the recipient bed.